These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 17355549

  • 21. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H, Jensen HB, Stenager E.
    Ugeskr Laeger; 2015 May 11; 177(20):956-60. PubMed ID: 26535431
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group.
    Lancet Neurol; 2019 Feb 11; 18(2):155-164. PubMed ID: 30554828
    [Abstract] [Full Text] [Related]

  • 23. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B.
    Neurologia; 2014 Jun 11; 29(5):257-60. PubMed ID: 24035293
    [Abstract] [Full Text] [Related]

  • 24. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.
    J Clin Pharmacol; 2016 Jul 11; 56(7):845-51. PubMed ID: 26608223
    [Abstract] [Full Text] [Related]

  • 25. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb 11; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 26. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Feb 11; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 27. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec 11; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 28. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
    Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R.
    Mult Scler; 2012 Feb 11; 18(2):219-28. PubMed ID: 21878454
    [Abstract] [Full Text] [Related]

  • 29. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H, Jensen HB, Stenager E.
    Ugeskr Laeger; 2014 Mar 17; 176(12A):. PubMed ID: 25350886
    [Abstract] [Full Text] [Related]

  • 30. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J, Feneberg W, Meier M, Pöllmann W.
    Int J Neurosci; 2014 Sep 17; 124(9):652-6. PubMed ID: 24392812
    [Abstract] [Full Text] [Related]

  • 31. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O.
    Eur Neurol; 2014 Sep 17; 72 Suppl 1():9-11. PubMed ID: 25278117
    [Abstract] [Full Text] [Related]

  • 32. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.
    J Neurol Sci; 2016 Nov 15; 370():263-268. PubMed ID: 27772772
    [Abstract] [Full Text] [Related]

  • 33. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P, Henze T, Zettl UK.
    Eur Neurol; 2014 Nov 15; 71(5-6):271-9. PubMed ID: 24525548
    [Abstract] [Full Text] [Related]

  • 34. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun 15; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 35. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group.
    Lancet; 2003 Nov 08; 362(9395):1517-26. PubMed ID: 14615106
    [Abstract] [Full Text] [Related]

  • 36. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M.
    Eur Neurol; 2016 Nov 08; 75 Suppl 1():4-8. PubMed ID: 26901343
    [Abstract] [Full Text] [Related]

  • 37. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG, Vila C.
    Brain Behav; 2018 May 08; 8(5):e00962. PubMed ID: 29761015
    [Abstract] [Full Text] [Related]

  • 38. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V, Centonze D.
    CNS Neurosci Ther; 2015 Mar 08; 21(3):215-21. PubMed ID: 25475413
    [Abstract] [Full Text] [Related]

  • 39. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.
    Wade DT, Makela PM, House H, Bateman C, Robson P.
    Mult Scler; 2006 Oct 08; 12(5):639-45. PubMed ID: 17086911
    [Abstract] [Full Text] [Related]

  • 40. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ.
    Mult Scler; 2004 Aug 08; 10(4):425-33. PubMed ID: 15327041
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.